← Immunocore Holdings plc
| Annual Trend | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $23.7m |
$25.7m
+8.52%
|
$30.1m
+17.32%
|
$26.5m
-11.93%
|
$143.7m
+441.99%
|
$249.4m
+73.53%
|
$310.2m
+24.37%
|
$400.0m
+28.95%
|
$430.8m
+7.69%
|
|
| Product revenue, net | — | — | $0 | $0 | $108.1m | — | — | — | — | |
| Pre-product revenue, net | — | — | $0 | $3.0m | $8.7m | — | — | — | — | |
| Collaboration revenue | — | — | $30.1m | $23.5m | $26.9m | — | — | — | — | |
| Total revenue from sale of therapies | — | — | $0 | $3.0m |
$116.8m
+3780.70%
|
— | — | — | $430.8m | |
| Cost of Goods and Services Sold | $17.7m |
$19.3m
+8.52%
|
$22.6m
+17.32%
|
$19.9m
-11.93%
|
$454k
-97.72%
|
$1.0m
+128.41%
|
$2.7m
+163.36%
|
$5.1m
+86.27%
|
$4.7m
-6.86%
|
|
| Cost Of Revenue | — | — | — | — | — | $1.0m |
$2.7m
+163.36%
|
$5.1m
+86.27%
|
$4.7m
-6.86%
|
|
| Cost of product revenue | — | — | $0 | $0 | ($454k) | — | — | — | — | |
| Net Interest Income | — | — | — | — | — | $12.8m |
$6.8m
-47.21%
|
$4.3m
-36.37%
|
$2.8m
-34.57%
|
|
| Gross Profit | $5.9m |
$6.4m
+8.52%
|
$7.5m
+17.32%
|
$6.6m
-11.93%
|
$143.3m
+2061.13%
|
$248.4m
+73.36%
|
$307.5m
+23.79%
|
$394.9m
+28.44%
|
$426.0m
+7.88%
|
|
| Research And Development | $83.6m | $100.0m | $74.8m | $73.2m | $89.2m | $163.5m | $222.2m | $274.9m | $284.5m | |
| Operating Lease Income | — | $185k | $460k | $108k | $0 | — | — | — | — | |
| Operating expenses: | ||||||||||
| Other Operating Income Expense | ($93.5m) | $0 | $109k | $0 | $0 | ($55.7m) | ($34.1m) | ($6.9m) | — | |
| Operating Income (Loss) | ($93.5m) |
($118.3m)
-26.61%
|
($86.2m)
+27.15%
|
($135.2m)
-56.81%
|
($39.6m)
+70.70%
|
($59.6m)
-50.60%
|
($70.5m)
-18.13%
|
($45.4m)
+35.63%
|
($22.6m)
+50.22%
|
|
| Interest Expense, Debt | — | — | — | — | — | — | $18.8m | $12.2m | $12.2m | |
| Interest Expense On Lease Liabilities | — | $2.9m | $2.4m | $1.7m | $1.8m | — | — | — | $12.2m | |
| Interest Income | — | — | — | — | — | $18.0m | $25.6m | $16.5m | $15.0m | |
| Net Non Operating Interest Income Expense | — | — | — | — | — | $12.8m | $6.8m | $4.3m | $2.8m | |
| Foreign Currency Transaction Gain (Loss), before Tax | — | — | — | — | — | ($13.2m) | ($3.4m) | $2.2m | — | |
| Gain On Sale Of PPE | — | — | — | ($243k) | $4k | — | — | — | $3k | |
| Gain On Sale Of Security | — | — | — | — | $14.2m | ($13.2m) | ($3.4m) | $2.2m | $2.6m | |
| Other Nonoperating Income (Expense) | — | — | — | — | $1.7m | ($897k) | $14.2m | $19.7m | — | |
| Non-operating expense | — | ($7.9m) | ($1.2m) | ($5.8m) | ($4.5m) | — | — | — | — | |
| Interest Expense (non-operating) | — | — | — | — | — | $5.2m | $18.8m | $12.2m | $12.2m | |
| Other Income Expense | — | — | — | — | — | ($14.1m) | $10.8m | $21.9m | $17.0m | |
| Pre-Tax Income | — | — | — | — | — | ($60.9m) | ($52.9m) | ($19.1m) | ($2.7m) | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | — | — | — | — | — | ($60.9m) | ($52.9m) | ($19.1m) | ($2.7m) | |
| Income tax credit | $16.5m | $22.3m | $13.3m | $9.4m | $2.9m | — | — | — | — | |
| Current Tax Expense (Income) | — | ($21.6m) | ($12.4m) | ($9.0m) | ($1.4m) | — | — | — | — | |
| Deferred Tax Expense (Income) | — | ($686k) | ($819k) | ($453k) | ($1.5m) | — | — | — | — | |
| Deferred Tax Expense (Income) Recognised In Profit Or Loss | — | $0 | ($790k) | ($484k) | ($1.4m) | — | — | — | — | |
| Current Income Tax Expense (Benefit) | — | — | — | — | — | ($240k) | $2.0m | $1.6m | $15.3m | |
| Income Tax Expense (Benefit) | — | — | — | — | — | ($5.6m) | ($1.9m) | $16.4m | $15.3m | |
| Net Income From Continuing And Discontinued Operation | — | — | — | — | — | ($55.3m) | ($51.1m) | ($35.5m) | ($18.1m) | |
| Earnings Per Share, Basic | ($3.32) | ($4.66) | ($2.79) | ($3.10) | ($0.90) | ($1.13) | ($1.02) | ($0.71) | ($0.36) | |
| Earnings Per Share, Diluted | ($3.32) | ($4.66) | ($2.79) | ($3.10) | ($0.90) | ($1.13) | ($1.02) | ($0.71) | ($0.36) | |
| Basic Earnings (Loss) Per Share | ($3.32) | ($4.66) | ($2.79) | ($3.10) | ($0.90) | ($1.13) | ($1.02) | ($0.71) | ($0.36) | |
| Diluted Earnings (Loss) Per Share | ($3.32) | ($4.66) | ($2.79) | ($3.10) | ($0.90) | ($1.13) | ($1.02) | ($0.71) | ($0.36) | |
| Common Stock, Dividends, Per Share, Declared | — | $0.00 | $0.00 | $0.00 | $0.00 | — | $0.00 | $0.00 | — | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | — | — | 48.9m | 50.0m | 50.3m | 51.7m | |
| Basic Average Shares | — | — | — | — | — | — | $50.0m | $50.3m | $51.7m | |
| Diluted Average Shares | — | — | — | — | — | — | $50.0m | $50.3m | $51.7m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | — | 48.9m | 50.0m | 50.3m | 51.7m | |
| Additional Financial Items | ||||||||||
| Depreciation Right of Use Assets | — | $2.5m | $2.5m | $1.5m | $1.8m | — | — | — | — | |
| Finance Income | $1.1m | $1.5m | $2.2m | $47k | $3.2m | — | — | — | — | |
| Impairment Loss Recognised In Profit Or Loss Intangible Assets Other Than Goodwill | — | $306k | $0 | $0 | — | — | — | — | — | |
| Profit Loss Before Tax | ($88.2m) | ($126.2m) | ($87.4m) | ($140.9m) | ($44.1m) | — | — | — | — | |
| Profit Loss From Operating Activities | ($93.5m) | ($118.3m) | ($86.2m) | ($135.2m) | ($39.6m) | ($59.6m) | ($70.5m) | ($45.4m) | — | |
| Loss before taxation | ($88.2m) | ($126.2m) | ($87.4m) | ($140.9m) | ($44.1m) | — | — | — | — | |
| Loss for the year | ($71.6m) | ($103.9m) | ($74.1m) | ($131.5m) | ($41.2m) | — | — | — | — | |
| Exchange differences on translation of foreign operations | $72k | ($99k) | $195k | ($74k) | ($3.2m) | — | — | — | — | |
| Diluted EPS | — | — | — | — | — | — | ($1.02) | ($0.71) | ($0.36) | |
| Diluted NI Availto Com Stockholders | — | — | — | — | — | ($55.3m) | ($51.1m) | ($35.5m) | ($18.1m) | |
| Normalized EBITDA | — | — | — | — | — | ($38.5m) | ($26.4m) | ($5.9m) | $13.0m | |
| Normalized Income | — | — | — | — | — | ($43.3m) | ($47.8m) | ($37.3m) | ($19.6m) | |
| Reconciled Depreciation | — | — | — | — | — | $4.1m | $4.2m | $3.3m | $3.6m | |
| Selling General And Administration | — | — | $45.7m | $88.4m | $93.7m | $144.5m | $155.8m | $165.4m | — | |
| Special Income Charges | — | — | — | ($243k) | $4k | — | — | — | $3k | |
| Tax Effect Of Unusual Items | — | — | — | — | — | ($1.2m) | ($124k) | $465k | $1.0m | |
| Tax Provision | — | — | — | — | — | ($5.6m) | ($1.9m) | $16.4m | $15.3m | |
| Tax Rate For Calcs | — | — | — | — | — | $0 | $0 | $0 | $0 | |
| Administrative Expense | — | $44.2m | $45.7m | $88.4m | — | — | — | — | — | |
| Employee Benefits Expense | — | $39.0m | $40.4m | $66.5m | $68.8m | — | — | — | — | |
| Expense Relating To Leases Of Low-Value Assets For Which Recognition Exemption Has Been Used | — | $33k | $19k | $0 | — | — | — | — | — | |
| Expense Relating To Short-Term Leases For Which Recognition Exemption Has Been Used | — | $486k | $296k | $0 | — | — | — | — | — | |
| Finance Costs | ($842k) | $9.4m | $3.4m | $5.8m | $7.7m | — | — | — | — | |
| Other Finance Cost | — | $2k | $0 | $0 | — | — | — | — | — | |
| Postemployment Benefit Expense Defined Contribution Plans | — | $1.2m | $1.0m | $1.0m | $1.4m | — | — | — | — | |
| Operating Expense | — | — | — | — | — | $308.0m | $377.9m | $440.3m | $448.6m | |
| Total other comprehensive (loss) / income for the year, net of tax | $3.7m | ($99k) | $195k | ($74k) | ($3.2m) | — | — | — | — | |
| Total comprehensive loss for the year, net of tax | ($67.9m) | ($104.0m) | ($73.9m) | ($131.6m) | ($44.4m) | — | — | — | — | |
| Total Unusual Items | — | — | — | — | — | ($13.2m) | ($3.4m) | $2.2m | $2.6m | |
| Total Expenses | — | — | — | — | — | $309.1m | $380.7m | $445.4m | $448.6m |